Sep 2026· Critical reviews in oncology/hematology· pp.
105596
· 1 citation· 95 references
Medicine
TL;DR
A context-dependent framework integrating macrophage heterogeneity, immunometabolism, spatial biology, biomarker development, and therapeutic decision-making to advance precision immunotherapy is proposed.
Abstract
Tumor-associated macrophages (TAMs) are abundant and functionally important components of the tumor microenvironment (TME), yet the molecular programs that distinguish pathogenic macrophage states from tissue-adaptive populations remain incompletely defined. Triggering receptor expressed on myeloid cells 2 (TREM2) has emerged as a key marker of specialized immunoregulatory macrophage states across multiple solid tumors. Accumulating evidence links TREM2⁺ macrophages to metabolic adaptation, immune evasion, and impaired antitumor immunity, although their biological functions vary substantially across tumor types, tissue niches, and disease settings. In this review, we synthesize current understanding of TREM2-associated immunobiology, including ligand recognition, signaling architecture, immunometabolic adaptation, and macrophage functional heterogeneity. We critically evaluate conflicting findings across tumor types and discuss how tissue context, macrophage ontogeny, and microenvironmental cues shape immune evasion, therapeutic responsiveness, and clinical outcomes. We further examine emerging therapeutic strategies targeting TREM2-associated myeloid programs, including antibody-based approaches, macrophage reprogramming, pathway modulation, and rational combination immunotherapy, while highlighting translational challenges, safety considerations, and biomarker-guided opportunities. Building on previous reviews of TREM2 signaling and tumor-associated myeloid biology, this review proposes a context-dependent framework integrating macrophage heterogeneity, immunometabolism, spatial biology, biomarker development, and therapeutic decision-making to advance precision immunotherapy.
Together, current evidence indicates that MDSCs represent context-dependent therapeutic nodes, while functional reprogramming, spatially resolved profiling, and patient stratification may improve immunotherapy outcomes.
Lisichen Zhu, Hui Liu, Sihan Zhang et al.· Cancer Letters· 1 citation
This chapter provides an integrated framework for understanding TAM biology across multiple regulatory dimensions, including ontogeny, plasticity, metabolism, epigenetic control, and spatial niche organization, and synthesizes current and emerging therapeutic strategies targeting TAM recruitment, survival, reprogrammin...
A. Elnaggar, Abdelrahman Elnaggar· Advances in Cancer Research· 0 citations
The tumor microenvironment (TME) is a complex ecosystem that dynamically regulates tumor progression and therapeutic responses. Within this environment, innate immune cells play prominent dual roles, acting as both critical mediators of anti-tumor surveillance and facilitators of tumor immune escape. This review compre...
Song-Hang Xing, Jia-Yu Zhang, Shuang Wang et al.· Frontiers in Immunology· 0 citations
A precision-immunotherapy framework is proposed in which treatment selection and sequencing could be informed by evolving immune states, and this framework complements established treatment approaches and defines testable hypotheses for prospective clinical studies.
S. M. Nashir Udden, Monira Obaid, Laurentiu M. Pop et al.· International Journal of Mol...· 0 citations
Tumor-associated macrophages (TAMs) play a pivotal role in tumor progression and immune evasion, with recent evidence indicating that metabolic reprogramming is crucial in determining their functional phenotype. Alterations in glucose, amino acid, and lipid metabolism are central to the regulation of TAMs plasticity,...
Wei-Feng Yuan, Yi-Ran Zhu, Yu-Xin Zhang et al.· Journal of Translational Med...· 0 citations
Current evidence supports the view that VISTA should be considered not simply as another inhibitory receptor, but as a dynamically regulated, myeloid-centered checkpoint axis with translational relevance in checkpoint-refractory and immune-excluded tumors.
Sarenur Teki̇ner, R. Karataş, Yaren Alras et al.· Medical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.